尼克洛萨米德强化TMEM16A,并诱导血管收缩
Pengfei Liang1, Yui Chun S Wan1, Kuai Yu2
1Department of Biochemistry, Duke University School of Medicine, Durham, NC, USA.
尼克洛萨米德,以前认为可以抑制TMEM16A通道,实际上在生理条件下增强了它们. 这一发现表明,它在治疗喘和COPD等疾病时应该谨慎使用.
科学领域:
- 分子药理学分子药理学
- 离子通道功能 离子通道功能
- 药物发现 药物发现
背景情况:
- 激活化通道TMEM16A是治疗喘和COPD等疾病的关键目标.
- 尼克洛萨米德是一种杀虫剂,作为TMEM16A抑制剂进行了研究,但表现出非目标效应.
研究的目的:
- 在生理条件下研究尼克洛萨米德对TMEM16A通道活性的实际作用.
- 确定尼古拉胺与TMEM16A相互作用的结合部位和机制.
- 为了评估尼古拉胺诱导的TMEM16A增强的生理后果.
主要方法:
- 计算建模和功能电生理学,以描述尼古拉胺-TMEM16A相互作用.
- 位点定向的突变发生,以探测已识别的结合位点.
- 对血管光滑肌细胞和小鼠中枢动脉进行实验,以评估生理效应.
主要成果:
- 尼克洛萨米德在生理度和电压下急剧增强TMEM16A通道活性.
- 在TMEM16A上确定了尼克洛萨米德的假定细胞外结合部位,并且在这里发生的突变降低了潜能.
- 尼克洛萨米德在血管光滑肌细胞中强化了内源性TMEM16A,导致的增加和动脉收缩.
结论:
- 在生理条件下,尼古拉胺作为TMEM16A通道的增强剂而不是抑制剂.
- 尼克洛萨米德作为TMEM16A抑制剂的临床使用需要谨慎,因为它具有意想不到的增强效应.
- 鉴定的结合部位为开发新型特异性TMEM16A调节器提供了基础.
更多相关视频
08:41Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
Published on: June 3, 2019
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
相关概念视频
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antihypertensive Drugs: Vasodilators
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Heart Failure Drugs: Inotropic Agents
Drugs Affecting Neurotransmitter Release or Uptake
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
